K C Takarinda1,2, R C Choto1, A D Harries2,3, T Mutasa-Apollo1, C Chakanyuka-Musanhu4. 1. AIDS and TB Department, Ministry of Health and Child Care, Harare, Zimbabwe. 2. International Union Against Tuberculosis and Lung Disease, Paris, France. 3. Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK. 4. World Health Organization Zimbabwe Country Office, Harare, Zimbabwe.
Abstract
Setting: Seven pilot sites in Zimbabwe implementing 6 months of isoniazid preventive therapy (IPT) for people living with the human immunodeficiency virus (PLHIV). Objectives: To determine, among PLHIV started on IPT, the completion rates for a 6-month course of IPT and factors associated with non-adherence. Design: A retrospective cohort study. Results: Of 578 patients, 466 (81%) completed IPT. Of the 112 patients who failed to complete IPT, 69 (60%) were lost to follow-up, 30 (27%) stopped treatment with no documented reasons, 8 (7%) developed toxicity/adverse reactions, 5 (5%) were documented as having drug stock-outs and the remainder transferred out or refused to continue treatment. Currently being on antiretroviral therapy (ART) (aOR 0.09, 95%CI 0.03-0.28) and receiving a ⩾2 month supply of isoniazid at the start of treatment were associated with a lower risk of not completing IPT, while missing clinic visits prior to starting IPT (aOR 5.25, 95%CI 2.10-13.14) was associated with a higher risk of non-completion. Conclusion: IPT completion rates in seven pilot sites of Zimbabwe were comparatively high, showing that IPT roll-out in public health facilities is feasible. Enhanced adherence counselling or active tracing among pre-ART patients and those with a history of loss to follow-up may improve IPT completion rates, along with synchronising IPT and ART resupplies.
Setting: Seven pilot sites in Zimbabwe implementing 6 months of isoniazid preventive therapy (IPT) for people living with the human immunodeficiency virus (PLHIV). Objectives: To determine, among PLHIV started on IPT, the completion rates for a 6-month course of IPT and factors associated with non-adherence. Design: A retrospective cohort study. Results: Of 578 patients, 466 (81%) completed IPT. Of the 112 patients who failed to complete IPT, 69 (60%) were lost to follow-up, 30 (27%) stopped treatment with no documented reasons, 8 (7%) developed toxicity/adverse reactions, 5 (5%) were documented as having drug stock-outs and the remainder transferred out or refused to continue treatment. Currently being on antiretroviral therapy (ART) (aOR 0.09, 95%CI 0.03-0.28) and receiving a ⩾2 month supply of isoniazid at the start of treatment were associated with a lower risk of not completing IPT, while missing clinic visits prior to starting IPT (aOR 5.25, 95%CI 2.10-13.14) was associated with a higher risk of non-completion. Conclusion: IPT completion rates in seven pilot sites of Zimbabwe were comparatively high, showing that IPT roll-out in public health facilities is feasible. Enhanced adherence counselling or active tracing among pre-ART patients and those with a history of loss to follow-up may improve IPT completion rates, along with synchronising IPT and ART resupplies.
Entities:
Keywords:
IPT; TB; Zimbabwe; human immunodeficiency virus
Authors: Jussi J Saukkonen; David L Cohn; Robert M Jasmer; Steven Schenker; John A Jereb; Charles M Nolan; Charles A Peloquin; Fred M Gordin; David Nunes; Dorothy B Strader; John Bernardo; Raman Venkataramanan; Timothy R Sterling Journal: Am J Respir Crit Care Med Date: 2006-10-15 Impact factor: 21.405
Authors: Alison D Grant; Salome Charalambous; Katherine L Fielding; John H Day; Elizabeth L Corbett; Richard E Chaisson; Kevin M De Cock; Richard J Hayes; Gavin J Churchyard Journal: JAMA Date: 2005-06-08 Impact factor: 56.272
Authors: B S C Uzochukwu; O E Onwujekwe; A C Onoka; C Okoli; N P Uguru; O I Chukwuogo Journal: Health Policy Plan Date: 2009-03-10 Impact factor: 3.344
Authors: Knut Lönnroth; Ernesto Jaramillo; Brian G Williams; Christopher Dye; Mario Raviglione Journal: Soc Sci Med Date: 2009-04-23 Impact factor: 4.634
Authors: Jonathan E Golub; Valeria Saraceni; Solange C Cavalcante; Antonio G Pacheco; Lawrence H Moulton; Bonnie S King; Anne Efron; Richard D Moore; Richard E Chaisson; Betina Durovni Journal: AIDS Date: 2007-07-11 Impact factor: 4.177
Authors: Bruce A Larson; Alana Brennan; Lynne McNamara; Lawrence Long; Sydney Rosen; Ian Sanne; Matthew P Fox Journal: Trop Med Int Health Date: 2010-06 Impact factor: 2.622
Authors: Hamish S F Fraser; Christian Allen; Christopher Bailey; Gerry Douglas; Sonya Shin; Joaquin Blaya Journal: J Med Internet Res Date: 2007-10-22 Impact factor: 5.428
Authors: Khai Hoan Tram; Florence Mwangwa; Gabriel Chamie; Mucunguzi Atukunda; Asiphas Owaraganise; James Ayieko; Vivek Jain; Tamara D Clark; Dalsone Kwarisiima; Maya L Petersen; Moses R Kamya; Edwin D Charlebois; Diane V Havlir; Carina Marquez Journal: AIDS Care Date: 2019-06-10
Authors: Collins Timire; John Z Metcalfe; Joconiah Chirenda; Jerod N Scholten; Barbara Manyame-Murwira; Mkhokheli Ngwenya; Ronnie Matambo; Kelvin Charambira; Herbert Mutunzi; Nico Kalisvaart; Charles Sandy Journal: Int J Infect Dis Date: 2019-07-27 Impact factor: 12.074
Authors: Masanja Robert; Jim Todd; Bernard J Ngowi; Sia E Msuya; Angella Ramadhani; Veryhel Sambu; Isaya Jerry; Martin R Mujuni; Michael J Mahande; James S Ngocho; Werner Maokola Journal: BMC Infect Dis Date: 2020-04-10 Impact factor: 3.090
Authors: D Thindwa; P MacPherson; A T Choko; M Khundi; R Sambakunsi; L G Ngwira; T Kalua; E L Webb; E L Corbett Journal: Int J Tuberc Lung Dis Date: 2018-03-01 Impact factor: 2.373
Authors: Yuli L Hsieh; Andreas Jahn; Nicolas A Menzies; Reza Yaesoubi; Joshua A Salomon; Belaineh Girma; Laurence Gunde; Jeffrey W Eaton; Andrew Auld; Michael Odo; Caroline N Kiyiika; Thokozani Kalua; Brown Chiwandira; James U Mpunga; Kuzani Mbendra; Liz Corbett; Mina C Hosseinipour; Ted Cohen; Amber Kunkel Journal: J Acquir Immune Defic Syndr Date: 2020-12-15 Impact factor: 3.731